Elevated international normalised ratios correlate with severity of injury and outcome

M A Noorbhai, MB ChB, FCS (SA), MMed (Surg); H M Cassimjee, MB ChB, DA (SA), FCS (SA), Cert Crit Care (SA), Cert Trauma Surg (SA); B Sartorius, PhD; D J J Muckart, MB ChB, FRCS, Cert Crit Care (SA), MMedSci

Department of General Surgery, School of Clinical Medicine, College of Health Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa

Trauma Unit and Trauma Intensive Care, Inkosi Albert Luthuli Central Hospital, Durban, South Africa

Discipline of Public Health Medicine, School of Nursing and Public Health, College of Health Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa

Trauma Unit and Trauma Intensive Care, Inkosi Albert Luthuli Central Hospital, Durban, South Africa

Corresponding author: M A Noorbhai (noorbhai@ukzn.ac.za)

Background. Haemorrhagic shock is the leading cause of preventable early deaths from trauma. Acute coagulopathy on admission to a trauma unit is associated with worse outcomes. The relationship of haemorrhage to early mortality remains consistent regardless of mechanism of injury. Haemorrhage and haemorrhagic shock are increasingly amenable to interventions that result in reductions in morbidity and mortality.

Objectives. To assess the prevalence of coagulopathy in patients admitted to the level 1 trauma unit at Inkosi Albert Luthuli Central Hospital, Durban, South Africa, and correlate it with in-hospital mortality.

Methods. A retrospective analysis of the first 1,000 patients admitted to the trauma unit during the years 2007 - 2011 was performed. The admission international normalised ratios (INRs) were correlated with Injury Severity Scores (ISSs) and in-hospital mortality. A multi-variable Poisson model with robust standard errors was used to assess the relationship between coagulopathy and mortality after adjustment for the confounding influence of age and gender. The data were analysed using the R statistics program.

Results. Of the 1,000 patients, 752 were male. There were 261 admissions directly from the scene and 739 inter-hospital transfers (non-scene). The mean INRs among survivors for all, scene and non-scene patients were 1.33, 1.30 and 1.34, respectively, and those among non-survivors 1.92, 2.01 and 1.88, respectively (p<0.001). The overall prevalence of coagulopathy was 48.7%, 46.9% in scene patients and 49.2% in non-scene patients. The mortality rate of scene patients with abnormal INR levels was 41.1% (adjusted relative risk (aRR) 3.59, 95% confidence interval (CI) 2.11 - 6.44; p=0.001) v. 25.1% for non-scene patients (aRR 1.67, 95% CI 1.15 - 2.05; p=0.004) (p<0.001).

Conclusions. There was a high prevalence of coagulopathy in our study. Raised admission INRs were associated with worse outcomes. There was a direct correlation between the INR and the ISS. INRs may offer predictive capabilities in resource-depleted environments where the ISS is not routinely calculated. Early recognition of acute coagulopathy may help reduce morbidity and mortality.


Objectives

To assess the prevalence of ACoTS at the level 1 trauma unit at Inkosi Albert Luthuli Central Hospital (IALCH), Durban, South Africa (SA), and correlate it with injury severity and in-hospital mortality.

Methods

Study design

The study was approved by the local ethics review board (Biomedical Research Ethics Committee, University of KwaZulu-Natal, Durban, ref. no. BE131/09).

Study setting

The study was conducted in the level 1 trauma unit at IALCH during the years 2007 - 2011. The trauma unit receives patients either directly from the scene of the incident or via inter-hospital transfers. Patients’ hospital numbers were retrieved from the existing trauma unit database and used to access each individual patient record from the computerised hospital information system. We used Soarian (Siemens, Germany), which allows real-time data entry including patient demographics, clinical notes, and serological and radiological investigations. The first 1,000 patients admitted to the trauma unit were included in the study. The data were de-identified prior to assessment.
The variables extracted included clinical parameters, mechanism of injury, INR, coagulation profile and in-hospital mortality. All blood results were those taken on admission to the resuscitation room via a direct-puncture arterial sample in a non-heparinised syringe. INR results were extracted from the electronic hospital laboratory database. The INR was analysed at the hospital laboratory using a Siemens BCS XP System (Siemens, Germany).[15] Innovin (Dade-Behring, Germany) was the thromboplastin used. An INR >1.2 was considered indicative of coagulopathy, in accordance with previous studies.[16,17]

Missing blood results in the first hour of admission were excluded from the study. The mechanism of injury was obtained from the patient’s electronic chart. The Injury Severity Score (ISS)[18] was computed after all injuries had been identified using the Abbreviated Injury Scale 90 reference book.[19] Death or survival was ascertained from the electronic hospital discharge notes.

The data were processed and analysed using the R statistics program (R Core Team, 2014).[20] INRs were recorded and analysed in 939 patients. The INR was dichotomised into ≤1.2 and >1.2. These were then correlated with ISS and in-hospital mortality. The bivariate analysis employed Pearson’s χ² test to determine the association between INR category and various outcomes/predictors, e.g. mortality. This analysis was then further stratified by scene/non-scene. Furthermore, a multivariable Poisson regression with robust standard errors was performed to assess the relationship between coagulopathy and mortality after adjustment for age and gender. Coefficients were exponentiated to represent adjusted relative risks (aRRs). A p-value of <0.05 was considered statistically significant.

### Results

#### Demographics

The first 1 000 patients were included in the study, of whom 752 were male (Table 1). The average age was 29 years (median 27, interquartile range (IQR) 21 - 36, standard deviation (SD) 15). The majority of admissions were from the 21 - 30-year age group (36.9%), with 1.6% aged >70 years and 16.5% <16 years.

#### Scene v. non-scene

There were 261 patients (26.1%) admitted directly from scene, the remaining 739 (73.9%) being inter-hospital transfers (non-scene).

#### INR in all admissions

INRs were not recorded in 61 patients, who were excluded from the analysis (Table 2). Of the remaining 939 patients, 454 (48.3%) were not found to have coagulopathy, while 485 (51.7%) had INRs >1.20. The overall mean INR was 1.46 (SD 1.77), (median 1.20, IQR 1.09 - 1.40). Survivors had significantly lower INRs (mean 1.33, median 1.18, IQR 1.07 - 1.33) than non-survivors (mean 1.92, median 1.35, IQR 1.14 - 1.68) (p<0.001).

The overall mortality rate was 21.9%, the rate being 15.4% in patients with a normal INR and 28.9% in those with a raised INR (p<0.001). Patients with an INR >1.20 were approximately two times more likely to die than those with a normal INR (adjusted RR 2.05, 95% CI 1.60 - 2.63) (Table 3). This is higher than the crude estimate as a result of negative confounding from age, i.e. patients with coagulopathy were significantly younger than their counterparts, and older individuals were more likely to die. There was a trend of

### Table 1. Characteristics of the patients in the study

<table>
<thead>
<tr>
<th></th>
<th>All patients</th>
<th>Scene patients</th>
<th>Non-scene patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, n</td>
<td>1 000</td>
<td>121/228</td>
<td>107/228</td>
</tr>
<tr>
<td>Age (years), mean (SD)</td>
<td>29 (15)</td>
<td>34 (15)</td>
<td>28 (16)</td>
</tr>
<tr>
<td>Males, n (%)</td>
<td>752 (75.2)</td>
<td>78 (64.5)</td>
<td>74 (69.2)</td>
</tr>
<tr>
<td>INR, mean (SD)</td>
<td>1.46 (1.77)</td>
<td>1.09 (0.07)</td>
<td>1.93 (2.61)</td>
</tr>
<tr>
<td>Coagulopathy prevalence, %</td>
<td>48.7</td>
<td>46.9</td>
<td>41.1</td>
</tr>
<tr>
<td>Mortality, %</td>
<td>21.9</td>
<td>12.4</td>
<td>16.3</td>
</tr>
<tr>
<td>ISS, median (SD)</td>
<td>All patients</td>
<td>25 (16)</td>
<td>Scene</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>18 (14)</td>
<td>29 (20)</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

### Table 2. Incidence of coagulopathy and mortality for scene and non-scene patients according to ISS

<table>
<thead>
<tr>
<th>ISS 0 - 15</th>
<th>ISS 16 - 30</th>
<th>ISS 31 - 45</th>
<th>ISS 46 - 60</th>
<th>ISS 61 - 75</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scene (N=228)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>45</td>
<td>14</td>
<td>48</td>
<td>42</td>
</tr>
<tr>
<td>Died, n (%)</td>
<td>1 (2.2)</td>
<td>1 (7.1)</td>
<td>6 (12.5)</td>
<td>9 (21.4)</td>
</tr>
<tr>
<td>Non-scene (N=711)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>43</td>
<td>73</td>
<td>163</td>
<td>162</td>
</tr>
<tr>
<td>Died, n (%)</td>
<td>5 (11.6)</td>
<td>14 (19.2)</td>
<td>21 (12.9)</td>
<td>29 (17.9)</td>
</tr>
</tbody>
</table>

Norm. = no coagulopathy; Coag. = coagulopathy (INR >1.20).
INR in scene patients
INRs were not recorded in 33 of the 261 patients admitted directly from the scene. Of the remaining 228 patients, 121 (53.1%) did not have coagulopathy, while 107 (46.9%) had INRs >1.20. Survivors had significantly lower INRs (mean 1.30, median 1.16, IQR 1.06 - 1.29) than non-survivors (mean 2.01, median 1.42, IQR 1.21 - 1.73) (p=0.01). The overall mortality rate was 25.9%, patients with a normal INR having a 12.4% mortality rate while the rate in those with a raised INR was 41.1% (p<0.001). Scene patients with an INR >1.20 were approximately four times more likely to die than scene patients with a normal INR (aRR 3.59, 95% CI 2.12 - 6.06) (Table 3).

INRs in non-scene patients
There were 739 patients transferred from other hospitals, among whom the INR was not recorded in 28. Of the remaining 711 patients, 361 (50.8%) had INRs within normal limits and 350 (49.2%) had INRs >1.20. Survivors had significantly lower INRs (mean 1.34, median 1.19, IQR 1.08 - 1.34) than non-survivors (mean 1.88, median 1.30, IQR 1.13 - 1.64) (p<0.001). The overall mortality rate was 20.7%, patients with a normal INR having a 16.3% mortality rate while the rate in those with a raised INR was 25.1% (p=0.004). Non-scene patients with an INR >1.20 were ~1.7 times more likely to die than non-scene patients with a normal INR (aRR 1.67, 95% CI 1.26 - 2.23) (Table 3).

Severity of injury
The ISS was calculated for each patient. The incidence of coagulopathy increased as the ISS increased. The median overall ISS was 18, being 20 for survivors (IQR 14 - 29) and 34 for non-survivors (IQR 25 - 50). The median ISS in scene patients who survived was 18 (IQR 9 - 28), the score for non-survivors being 50 (IQR 34 - 66). The mean ISS score for non-scene patients who survived was 22 (IQR 16 - 29) and that for non-survivors 30 (IQR 18 - 41).

Among scene patients, the lowest ISSs associated with coagulopathy were 16 - 30, with ISSs of 31 - 45 in non-scene patients. After adjusting for age and gender, increasing ISS was significantly associated with an increased risk of mortality among all patients as well as when stratified as scene/non-scene (Table 3). Overall a one-unit increase in ISS after adjustment was associated with an ~4% increased risk of mortality (aRR 1.04; p<0.001). This effect size was similar when stratified by scene/non-scene.

Among patients who died, there was a greater degree of coagulopathy for every ISS interval for both scene and non-scene patients. Table 2 illustrates the incidence of coagulopathy and mortality in scene and non-scene patients categorised by ISS. The presence of coagulopathy was also significant when deaths in resuscitation, in the operating theatre and within 24 hours of ICU admission were excluded (Fig. 2).

The majority of patients with an INR of <1.30 have a higher probability of being alive despite their injury severity. However, the INR interval 1.30 - 1.49 shows a progressively increased probability of death as the ISS increases. Patients with an INR >1.49 have a high probability of death across all ISS intervals. In this study, the overall prevalence of coagulopathy was 34.1% for an ISS <15, 47.3% for an ISS of 16 - 30, 57.1% for an ISS of 31 - 45 and 70.1% for an ISS >45. Both the scene and non-scene groups had an increased prevalence with increasing ISS scores.

Discussion
Invented by Kirkwood[21] in an effort to consistently record prothrombin ratios, the INR is the ratio of patient's prothrombin time (PT) divided by the mean normal PT raised to the power of the International Sensitivity Index (ISI). Before the INR was available, many different prothrombin time

Table 3. Multiple Poisson regression analysis for all, scene and non-scene patients, adjusted for age and male gender

<table>
<thead>
<tr>
<th>Variable</th>
<th>INR model</th>
<th>ISS model</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>aRR</td>
<td>95% CI</td>
</tr>
<tr>
<td>All</td>
<td>1.92</td>
<td>1.49 - 2.48</td>
</tr>
<tr>
<td>Age</td>
<td>1.02</td>
<td>1.01 - 1.03</td>
</tr>
<tr>
<td>Male</td>
<td>1.10</td>
<td>0.83 - 1.46</td>
</tr>
<tr>
<td>Scene</td>
<td>3.68</td>
<td>2.11 - 6.44</td>
</tr>
<tr>
<td>Age</td>
<td>1.01</td>
<td>1.00 - 1.02</td>
</tr>
<tr>
<td>Male</td>
<td>0.97</td>
<td>0.62 - 1.50</td>
</tr>
<tr>
<td>Non-scene</td>
<td>1.54</td>
<td>1.15 - 2.05</td>
</tr>
<tr>
<td>Age</td>
<td>1.02</td>
<td>1.01 - 1.03</td>
</tr>
<tr>
<td>Male</td>
<td>1.21</td>
<td>0.83 - 1.76</td>
</tr>
</tbody>
</table>

Fig. 1. INR intervals and associated outcomes.
ratios were recorded based on the type of thromboplastin reagent used. Kirkwood also produced the ISI, which allowed the calibration of different thromboplastins to an international standard. The INR is therefore a more precise way than other methods of accurately recording the prothrombin ratios and the degree of coagulation.

The INR and PT are measures of the extrinsic pathway of coagulation. The PT measures the following clotting factors: factor I (fibrinogen), factor II, factor V, factor VII and factor X. The activated partial thromboplastin time (aPTT) measures factors VIII, IX and XII of the intrinsic pathway and factors V, X, fibrinogen and prothrombin of the common pathway. The INR/PT and aPTT are therefore screening tests for detecting critical clotting factor deficits that impair haemostasis.[22]

Rizoli et al.[22] analysed clotting factor levels in patients with severe trauma (ISS ≥16). They found that patients without a critical clotting factor deficiency all had normal INRs and aPTTs, i.e. that the INR and aPTT had a specificity of 100% for critical clotting factor deficits.[22] Factor V was found to be particularly low compared with other clotting factors.[22] They also noted that thromboelastography was inferior to INR or aPTT in identification of critical clotting factor deficits.[22] Critical clotting factor deficiencies occur immediately after injury, before substantial fluid resuscitation, and are associated with poor outcomes. At the time of our study, neither ROTEM products (TEM, Switzerland) nor a point-of-care (POC) INR device were available in our unit. Our findings suggest that a raised INR is associated with increased mortality rates and that both the INR and the ISS can be used to identify patients at risk.

Incidence of ACoTS

The prevalence of coagulopathy in our study is higher than the rates reported by Brohi et al.[24] ACoTS is reported in 25% of trauma patients, with an associated four-fold increase in mortality.[23,24] Wafaisade et al.[24] and Maegele et al.[28] reported prevalence rates of coagulopathy at admission of 36.1% and 34.2%, respectively. Similar rates were seen in combat casualties.[27] In our study, the overall prevalence of coagulopathy was 48.7%, with prevalences of 46.9% and 49.2% in scene and non-scene patients, respectively.

We further identified prevalence rates for each subgroup of ISS. There was an overall increased prevalence of coagulopathy as ISSs increased. This was true for both scene and non-scene patients. The mortality rate for patients with coagulopathy in each ISS category was higher than that for patients with no coagulopathy. However, among the non-scene patients the mortality rates for both patients with normal coagulation and those with coagulopathy were similar for each ISS category. This suggests that these patients may benefit from earlier direct referral to a level 1 trauma unit. In resource-depleted environments and in regional and district hospitals where ISSs are not calculated, INRs may be used to identify high-risk patients.

Our results show that the incidence of coagulopathy was increased with increases in ISS. Increased tissue injury manifested by the ISS is related to a proportional increase in coagulopathy. The ISS risk ratio for the entire study population suggested that as the ISS increases, the risk of dying increases significantly.

Study limitations

INRs can be deranged in conditions other than trauma, including chronic liver disease, and as a result of anticoagulation therapies. The median age and IQR in our study suggests that these conditions were unlikely. Clotting tests were performed at 37°C and not at body temperature. Similar studies report similar limitations.[14,23,28] Further analysis of the non-scene group, including amount and type of fluid administration, could offer further insight into the increased prevalence of coagulopathy in this group.

Recommendations

While ISSs are also predictive of poor outcomes, these scores are not routinely calculated in regional and district hospitals. The INR may offer predictive capabilities to the attending doctor in resource-depleted environments. POC devices offer the opportunity to obtain INRs faster than conventional coagulation tests.

Conclusions

ACoTS is often present in trauma patients, particularly the severely injured. The overall prevalence of coagulopathy was comparable to previous studies and was high in both direct admissions and inter-hospital transfers. Raised admission INRs were associated with worse outcomes. There was a direct correlation between INRs and ISSs. The INR may help identify patients at risk in resource-depleted environments. Further studies will assist in identifying optimal overall cut-off values for INR, ISS and ISS subgroups that would help identify patients at risk. Earlier recognition of ACoTS may help reduce mortality.

Acknowledgements. We thank Mr M Habib Noorbhai and Mrs Shireen Khan for their assistance with data collection and their support.

Author contributions. MAN, through a literature review, analysed the feasibility of the study, designed the study, obtained the necessary approvals, did data management and analysis, data tabulation and data illustration, and wrote the manuscript. HMC provided supervision, guided the study design, literature review and data analysis, and read the final manuscript. BS did the statistical analysis and read the statistical aspects of the final manuscript. DJJM computed the ISSs, provided study guidance and read the final manuscript.


Accepted 17 December 2015.